Day: January 14, 2025

TORONTO and TAMPA, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) — Voxtur Analytics Corp. (TSXV: VXTR; OTCQB: VXTRF) (“Voxtur” or the “Company”), a North American technology company creating a more transparent and accessible real estate lending ecosystem, today announces that its Board of Directors has initiated a process to identify, examine and consider strategic and financial options available to the Company with the ultimate view of enhancing value for our shareholders, employees and clients. Strategic and financial options may include, but are not limited to, recapitalization, a sale of all or a portion of the Company’s assets, merger, or any combination thereof, and continued execution of the Company’s business plan. The Board of Directors has established a Special Committee comprised of independent directors to oversee the process...

BELGRADE, Mont., Jan. 14, 2025 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today announced that it has secured a five-year $20.1 million Indefinite Delivery Indefinite Quantity (IDIQ) contract with the U.S. Department of the Interior (DOI) for two air attack and surveillance aircraft in support of fire and resource management activities and other government work for the Bureau of Land Management (BLM) Alaska Fire Service. “Our air attack and surveillance fleet is ideally suited to serve the DOI and the State of Alaska to support their fire and resource management activities, including fire detection, logistical support and aerial observation, as well as the provision of information to initial attack...

TORONTO, Jan. 14, 2025 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX: CSU) and Topicus.com Inc. (TSXV: TOI) today announced that Topicus’ subsidiary Total Specific Solutions (TSS) B.V. (“TSS”) has entered into a binding agreement with CIPAL NV and Mr. Schaubroeck in respect of the sale and transfer of all issued and outstanding shares in the capital of Cipal Schaubroeck NV to TSS. Cipal Schaubroeck NV (“CP”) is a Belgium-based vertical market software provider active in the local government vertical with annual gross revenues of approximately €110M in 2024. CP employs over 590 employees (561 full time equivalents). The transaction is currently expected to close in Q1 2025, subject to the satisfaction of certain standard closing conditions including clearance from the Belgian Interfederal Screening Commission. About Topicus.com Topicus.com...

— Interim data from Cohort 4 expected Q1 2025 — MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced it has opened three clinical trial sites in Eastern Europe. These sites in Romania and Bulgaria are actively recruiting patients along with the four open sites in the United States, for Pasithea’s PAS-004 Phase 1 trial. In Eastern Europe, Pasithea is working with Arensia Exploratory Medicine, Institute of Oncology Bucharest, Arensia Exploratory Medicine, Institute of Oncology Cluj-Napoca, and Arensia Exploratory Medicine, Multiprofile Hospital for Active Treatment...

HAMILTON, Bermuda, Jan. 14, 2025 (GLOBE NEWSWIRE) — Enstar Group Limited (“Enstar”) (Nasdaq: ESGR) announced today its Lloyd’s syndicate (“Syndicate 2008”), managed by Enstar Managing Agency Limited, has agreed a ground-up loss portfolio transfer (“LPT”) with Atrium Syndicate 609, managed by Atrium Underwriters Limited. The transaction involves Syndicate 609’s discontinued portfolios, comprising Marine Treaty Reinsurance, Property Treaty Reinsurance and US Contractors General Liability. Under the terms of the LPT, Atrium Syndicate 609 will cede net loss reserves of approximately $196 million, based on Atrium’s carried reserves as at Q3 2024, to Enstar’s Syndicate 2008. The reinsurance relates to business underwritten in the 2023 and prior years of account, with all claims handling transferring to Syndicate 2008. The transaction...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose emergency treatments to patients, customers and communities in need Focus remains on increasing access, raising awareness and ensuring strong supply to meet the ongoing demand of naloxone nasal sprayGAITHERSBURG, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO® (naloxone HCl) Nasal Spray, an 8 mg naloxone agent that is approved for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.1...

CLEVELAND, Jan. 14, 2025 (GLOBE NEWSWIRE) — Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is presenting today at the 43rd Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera Health’s business. “I am pleased to announce that Sotera Health delivered another year of top-line growth in 2024,” said Mr. Petras. “We expect full-year revenues will be approximately $1.1 billion, representing growth of nearly 5% versus 2023 and more than 5% growth on a constant currency basis. The growth we experienced in 2024 is a testament to the resiliency of our business model, which allows...